|
Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS) |
Jan 2021 |
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
|
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) |
Mar 2021 |
Cancers |
Chronic Myelomonocytic Leukaemia (CMML), Myelodysplastic Syndromes (MDS) |
|
RNA splicing as a therapeutic target in myelodysplastic syndromes |
Dec 2024 |
Seminars in Hematology |
Myelodysplastic Syndromes (MDS) |
|
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review |
Jul 2023 |
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
|
Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome |
May 2024 |
Journal of Pediatric Hematology/Oncology |
Aplastic Anemia |
|
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
|
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial |
Aug 2020 |
Lancet Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Safety and efficacy of danicopan in patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis |
Oct 2024 |
Expert Review of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study |
Apr 2024 |
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
Jul 2020 |
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
